Spark Biopharma Inc. has prepared and tested stimulator of interferon genes protein (STING; TMEM173) agonists that are reported to be useful for the treatment of cancer.
Mitogen-activated protein kinase kinase kinase 13 (MAP3K13; LZK) inhibitors reported to be useful for the treatment of cancer have been described in a recent U.S. Department of Health and Human Services patent.
Research at KHR Biotec GmbH has led to the development of eukaryotic initiation factor 4A (elF4A) and GTPase mutant inhibitors potentially useful for the treatment of cancer, craniofacial syndrome and neurofibromatosis type I.
(Azacycloalkyl)methoxy-substituted benzamides acting as trace amine-associated receptor 1 (TAAR1; TAR1) agonists have been described in a recent Accellena Research and Development LLC patent.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has described 5-fluoro-7h-pyrrolo[2,3-d] pyrimidine compounds as Wee1-like protein kinase (Wee1) inhibitors potentially useful for the treatment of cancer.
Researchers from Centre National de la Recherche Scientifique, Inserm, Institut Curie and Uniwersytet im Adama Mickiewicza have prepared nitrogen-containing salinomycin derivatives reported to be useful for the treatment of cancer.
Research at Artica Therapeutics BV has led to the development of C-C chemokine receptor type 2 (CCR2B) antagonists reported to be useful for the treatment of cancer.
RSS
